|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cyclin D1 (G870A) polymorphism and risk of cervix cancer:a ease control study in north Indian population显示文摘 | Satinder K Chander SR Pushpinder K | 2008 | Mol Cell Biochem2008，315，12： | 1 |
| 2 | Interaction of passive smoking with GST (GSTM1 , GSTT1 and GSTP1 ) genotypes in the risk of cervical cancer in India显示文摘 | Sobti RC Satinder K Pushpinder K | 2006 | Cancer Genetics and Cytogenetics2006，166，： | 1 |
| 3 | Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population 显示文摘 | Satinder K Chander SR Pushpinder K | 2008 | Mol Cell Biochem2008，315，12： | 1 |
| 4 | Cyclin D1 (G870A)polymorphism and risk of cervix cancer:a case control study in north Indian population 显示文摘 | Satinder K Chander SR Pushpinder K | 2008 | Mol Cell Biochem2008，315，12： | 1 |
| 5 | Interaction of passive smoking with GST (GSTM1 ,GSTT1 ,and GSTP1 ) genotypes in the risk of cervical cancer in India显示文摘 | Sobti RC Satinder K Pushpinder K | 2006 | Cancer Genetics and Cytogenetics2006，166，2： | 1 |
| 6 | Cyclin D1 (GB70A) polymorphism and risk of cervix cancer: a case control study in north Indian population显示文摘 | Satinder K SR Chander K Pushpinder | 2008 | Mol Cell Biochem2008，315，12： | 1 |
| 7 | Interaction of passive smoking with GST(GSTM1,GSTT1,and GSTP1) genotypes in the risk of cervical cancer in India显示文摘 | Sobti R C Satinder K Pushpinder K | 2006 | Cancer Genetics and Cytogenetics2006，166，2： | 1 |
| 8 | Biology and chemistry of Ginkgo biloba 显示文摘 | Bikram S Pushpinder K Gopichand | 2008 | Fitoterapia2008，79，6： | 1 |
| 9 | Cyclin D1(G870A) polymorphism and risk of cervix cancer:a case control study in north Indian population显示文摘 | Satinder K Chander SR Pushpinder K | 2008 | Mol Cell Biochem2008，315，12： | 1 |
| 10 | Patch testing and cross sensitivity study of adverse cutaneous drug reactions due to anticonvulsants: A preliminary report显示文摘AIM To evaluate the utility of patch test and cross-sensitivity patterns in patients with adverse cutaneous drug reactions(ACDR) from common anticonvulsants. METHODS Twenty-four(M:F = 13:11) patients aged 18-75 years with ACDR from anticonvulsants were patch tested 3-27 mo after complete recovery using carbamazepine, phenytoin, phenobarbitone, lamotrigine, and sodium valproate in 10%, 20% and 30% conc. in pet. after informed consent. Positive reactions persisting on D3 and D4 were considered significant. RESULTS Clinical patterns were exanthematous drug rash with or without systemic involvement(DRESS) in 18(75%), Stevens-Johnsons syndrome/toxic epidermal necrolysis(SJS/TEN) overlap and TEN in 2(8.3%) patients each, SJS and lichenoid drug eruption in 1(4.2%) patient each, respectively. The implicated drugs were phenytoin in 14(58.3%), carbamazepine in 9(37.5%), phenobarbitone in 2(8.3%), and lamotrigine in 1(4.7%) patients,respectively. Twelve(50%) patients elicited positive reactions to implicated drugs; carbamazepine in 6(50%), phenytoin alone in 4(33.3%), phenobarbitone alone in 1(8.3%), and both phenytoin and phenobarbitone in 1(8.33%) patients, respectively. Cross-reactions occurred in 11(92%) patients. Six patients with carbamazepine positive patch test reaction showed cross sensitivity with phenobarbitone, sodium valproate and/or lamotrigine. Three(75%) patients among positive phenytoin patch test reactions had cross reactions with phenobarbitone, lamotrigine, and/or valproate. CONCLUSION Carbamazepine remains the commonest anticonvulsant causing ACDRs and cross-reactions with other anticonvulsants are possible. Drug patch testing appears useful in DRESS for drug imputability and cross-reactions established clinically. | TN Shiny Vikram K Mahajan Karaninder S Mehta Pushpinder S Chauhan Ritu Rawat Rajni Sharma | 2017 | World Journal of Methodology2017，7，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员